Soluflazine | CAS#112415-83-5 | adenosine transport inhibitor

MedKoo Cat#: 461077 | Name: Soluflazine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Soluflazine is a potent adenosine transport inhibitor.

Chemical Structure

Soluflazine HCl

CAS#112415-83-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 461077

Name: Soluflazine HCl

CAS#: 112415-83-5 (HCl)

Chemical Formula: C28H32Cl4FN5O2

Exact Mass:

Molecular Weight: 631.39

Elemental Analysis: C, 53.26; H, 5.11; Cl, 22.46; F, 3.01; N, 11.09; O, 5.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

734499-99-1 (free base) 112415-83-5 (HCl)

Synonym

Soluflazine; R 64719; R-64719; R64719;

IUPAC/Chemical Name

(S)-4-(2-((2,6-dichlorophenyl)amino)-2-oxoethyl)-1-((R)-4-(4-fluorophenyl)-4-(pyridin-3-yl)butyl)piperazine-2-carboxamide dihydrochloride

InChi Key

KQZLAOQGNIIITJ-KHAYEEQJSA-N

InChi Code

InChI=1S/C28H30Cl2FN5O2.2ClH/c29-23-6-1-7-24(30)27(23)34-26(37)18-35-14-15-36(25(17-35)28(32)38)13-3-5-22(20-4-2-12-33-16-20)19-8-10-21(31)11-9-19;;/h1-2,4,6-12,16,22,25H,3,5,13-15,17-18H2,(H2,32,38)(H,34,37);2*1H/t22-,25+;;/m1../s1

SMILES Code

O=C([C@H]1N(CCC[C@H](C2=CC=C(F)C=C2)C3=CC=CN=C3)CCN(CC(NC4=C(Cl)C=CC=C4Cl)=O)C1)N.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 631.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: O'Connor SD, Stojanovic M, Radulovacki M. The effect of soluflazine on sleep in rats. Neuropharmacology. 1991 Jun;30(6):671-4. PubMed PMID: 1922685. 2: Ashton D, De Prins E, Willems R, Van Belle H, Wauquier A. Anticonvulsant action of the nucleoside transport inhibitor, soluflazine, on synaptic and non-synaptic epileptogenesis in the guinea-pig hippocampus. Epilepsy Res. 1988 Mar-Apr;2(2):65-71. PubMed PMID: 3197688. 3: Ashton D, Willems R, De Prins E, Van Belle H, Wauquier A. The nucleoside-transport inhibitor soluflazine (R 64 719) increases the effects of adenosine in the guinea-pig hippocampal slice and is antagonized by adenosine deaminase. Eur J Pharmacol. 1987 Oct 27;142(3):403-8. PubMed PMID: 3428353. 4: Boissard CG, Gribkoff VK. The effects of the adenosine reuptake inhibitor soluflazine on synaptic potentials and population hypoxic depolarizations in area CA1 of rat hippocampus in vitro. Neuropharmacology. 1993 Feb;32(2):149-55. PubMed PMID: 8383814. 5: Ferrandon P, Barcelo B, Perche JC, Schoffs AR. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol. 1994;8(5):446-52. PubMed PMID: 7875639. 6: O'Connor SD, Hawkins M, Radulovacki M. The effect of soluflazine on adenosine receptors in the rat brain. Neuropharmacology. 1991 Jan;30(1):93-5. PubMed PMID: 2046882. 7: Phillis JW, O'Regan MH, Walter GA. Effects of two nucleoside transport inhibitors, dipyridamole and soluflazine, on purine release from the rat cerebral cortex. Brain Res. 1989 Mar 6;481(2):309-16. PubMed PMID: 2720383. 8: Paproski RJ, Visser F, Zhang J, Tackaberry T, Damaraju V, Baldwin SA, Young JD, Cass CE. Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity. Biochem J. 2008 Sep 1;414(2):291-300. doi: 10.1042/BJ20080074. PubMed PMID: 18462193. 9: Hammond JR. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):373-82. PubMed PMID: 10763851. 10: IJzerman AP, Voorschuur AH. The relationship between ionization and affinity of nucleoside transport inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):336-41. PubMed PMID: 2280800. 11: Griffith DA, Conant AR, Jarvis SM. Differential inhibition of nucleoside transport systems in mammalian cells by a new series of compounds related to lidoflazine and mioflazine. Biochem Pharmacol. 1990 Nov 15;40(10):2297-303. PubMed PMID: 2244931. 12: Gleiter CH, Brause M, Delabar U, Zebski H, Eckardt KU. Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats. Kidney Int. 1997 Aug;52(2):338-44. PubMed PMID: 9263988. 13: Van Belle H, Goossens F, Wynants J. Biochemical and functional effects of nucleoside transport inhibition in the isolated cat heart. J Mol Cell Cardiol. 1989 Aug;21(8):797-805. PubMed PMID: 2778816. 14: Hammond JR. Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells. J Pharmacol Exp Ther. 1991 Nov;259(2):799-807. PubMed PMID: 1941627. 15: Baer HP, Serignese V, Moorji A, Van Belle H. In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn Schmiedebergs Arch Pharmacol. 1991 Apr;343(4):365-9. PubMed PMID: 1852220. 16: Sarda N, Cespuglio R, Gharib A, Reynaud D. [Role of hypothalamic adenosinergic systems in regulating states of wakefulness in the rat]. C R Acad Sci III. 1989;308(17):473-8. French. PubMed PMID: 2499406. 17: Ogbunude PO, Baer HP. Competition of nucleoside transport inhibitors with binding of 6-[(4-nitrobenzyl)-mercapto]purine ribonucleoside to intact erythrocytes and ghost membranes from different species. Biochem Pharmacol. 1990 Apr 1;39(7):1199-204. PubMed PMID: 2322305. 18: Conant AR, Jarvis SM. Nucleoside influx and efflux in guinea-pig ventricular myocytes. Inhibition by analogues of lidoflazine. Biochem Pharmacol. 1994 Aug 30;48(5):873-80. PubMed PMID: 8093099. 19: Visser F, Sun L, Damaraju V, Tackaberry T, Peng Y, Robins MJ, Baldwin SA, Young JD, Cass CE. Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover. J Biol Chem. 2007 May 11;282(19):14148-57. Epub 2007 Mar 22. PubMed PMID: 17379602. 20: Van Belle H. Adenosine transformation by human red blood cell membranes. Fundam Clin Pharmacol. 1995;9(2):207-8. PubMed PMID: 7628837.